MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
To read the full story
Related Article
- Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
March 14, 2018
- MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
BUSINESS
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
- Novel β-Lactamase Inhibitor Nacubactam Safe and Effective: Meiji
March 17, 2025
- AbbVie Files Migraine Med Atogepant in Japan
March 17, 2025
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
- Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…